Scott BriggsPresident & CEO
Ed CincaChief Commercial Officer
Kim ClarkeGeneral Counsel & Compliance
Mark ConleyChief Financial Officer
Joan GrayHead of Human Resources
James HarringtonGlobal Chief Intellectual Property Counsel
Danielle HoltschlagU.S. Sales Channels
Rohan LathiaHead of Business Development
Bruce Mitlak, M.D.Chief Medical Officer
Peter SchwartzmanCorporate Finance
Chhaya ShahChief Business Officer
Bob ValentineBusiness Intelligence & Digital – U.S. Commercial
President & CEO
Scott Briggs is a senior pharmaceutical commercial executive with over 25 years’ experience in pharmaceutical marketing and sales, strategic planning, and business management. Scott most recently served as Chief Commercial Officer of Sebela Pharmaceuticals, a specialty pharmaceutical company with market leading brands in gastroenterology, women’s health, and dermatology. In this role he led all commercial functions, substantially growing sales of its branded products, planned, and successfully implemented multiple product launches and acted as a senior member of the Executive Leadership team. Prior to joining Sebela Pharmaceuticals, Mr. Briggs served as Vice President, Marketing and Sales at Noven Pharmaceuticals, where he led all commercial operations. Previously, he also served Noven in the roles of Vice President – women’s health sales, and Executive Director – marketing and managed markets. Prior to joining Noven, Scott was senior director of marketing for JDS Pharmaceuticals. He also held several leadership positions in management and marketing with Ortho-McNeil Pharmaceuticals (part of Johnson & Johnson). Mr. Briggs holds a BA in Business Administration from Villanova University.
Chief Commercial Officer
Ed is a recognized leader in the pharmaceutical industry, with diversified, progressive experience centered around small to multibillion-dollar product launches and commercialization. He brings with him 20 years of experience in pharma and biotech with strong emphasis on business strategy, innovation, execution, and transformation. Ed’s most recent role was as SVP/GM at Currax Pharmaceuticals, which is an industry leader in the treatment of obesity and smoking cessation. In this capacity, he led the relaunch of a mature brand leading to new market inroads, while simultaneously planning for the commercialization of a new product. Before that, he had a very successful career with Novo Nordisk, Inc. (NNI) serving as an Leadership team member and Vice President, Head of Cardiometabolic portfolio where he directed the launches of Ozempic, Rybelsus and Wegovy.
General Counsel & Compliance
Kim serves as the company’s General Counsel and joined Radius in 2021. She brings two decades of experience to her role having worked in both corporate and private practice focused on the biotech/pharmaceutical industry. Prior to joining Radius, Kim was Senior Counsel, US Pharma legal operations for GlaxoSmithKline.
Chief Financial Officer
Mark serves as our Chief Financial Officer and joined the company in 2022. He is a Certified Public Accountant with over 30 years of experience in publicly listed companies. Prior to joining Radius, Mark previously held senior leadership roles at Kaleido Biosciences, Valeritas, Inc., as well as Thermo Fisher Scientific, Inc.
Head of Human Resources
Joan serves as the company’s Head of Human Resources. She joined Radius in April 2021. She has over 25 years of human resources experience having worked in public and private organizations in the financial, manufacturing, healthcare, and clinical research industries. Prior to joining Radius, Joan was a Global HR Business Partner with PPD.
Global Chief Intellectual Property Counsel
Jim serves as the Chief intellectual property counsel at Radius Health. He joined Radius in June 2020. He is a global legal executive with extensive experience as a general legal and intellectual property strategist. Prior to joining Radius, Jim was Senior Vice President Intellectual Property at Novartis and Takeda / Shire.
U.S. Sales Channels
Danielle Holtschlag serves as Head of U.S. Sales Channels and joined the company in September 2021. She has over two decades of sales leadership experience including operations, training, and segment management. Prior to joining Radius, Danielle worked at PharmaEssentia and Genzyme.
Head of Business Development
Rohan Lathia serves as Head of Corporate & Business Development and joined the company in July 2021. Prior to Radius, he worked in business development at Biogen after spending time at Bain and Company and Trinity Partners.
Bruce Mitlak, M.D.
Chief Medical Officer
Bruce Mitlak serves as our Chief Medical Officer and joined the company in 2016. Prior to Radius, Bruce was a Distinguished Medical Fellow at Eli Lilly and Company for more than two decades where he supported the development of novel treatments for musculoskeletal disorders and women’s health.
He has authored more than 90 original articles and chapters including publications in the New England Journal of Medicine and JAMA.
Peter Schwartzman leads our Corporate Finance efforts to actively manage the company’s capital structure and balance sheet. He joined the company in October 2020 and has more than two decades of portfolio and investment management experience. Prior to Radius, he worked at Piney Lake Capital Management, BlackRock, Alliance Capital Management, and Moody’s.
Chief Business Officer
Chhaya Shah has oversight of the company’s development and technical operations efforts for the abaloparatide and elacestrant assets and joined the company in July 2018. Prior to Radius, she was Senior Vice President at Synergy Pharmaceuticals as well as held significant leadership roles at Shire Pharmaceuticals, Wyeth Pharmaceuticals, and Abbott Laboratories.
Chhaya leads the company’s partnership and relationship with Menarini Group in support of the elacestrant molecule and program.
Business Intelligence & Digital – U.S. Commercial
Bob Valentine serves as Head of Business Intelligence & Digital for the U.S. Commercial group and joined the company in March 2021. Prior to Radius, Bob was a consultant in L.E.K. Consulting’s Life Sciences practice, focused on growth strategy, M&A, and operations & planning.
Bob has held various business roles at Shire, Regeneron, and Genzyme with experience in process engineering, business development, and operational execution.